Skip to main content
. Author manuscript; available in PMC: 2011 Feb 1.
Published in final edited form as: J Allergy Clin Immunol. 2010 Feb;125(2):359–366.e3. doi: 10.1016/j.jaci.2009.10.037

Figure 3.

Figure 3

The figures present the adjusted mean values for each continuous outcome measure: a: annual prednisone course rate; b: annual urgent care rate; c: prebronchodilator FEV1 % predicted; d: prebronchodilator FEV1/FVC; e: bronchodilator reversibility, f: log methacholine FEV1 PC20; g: total eosinophil count; and h: serum IgE in the remitting (Inline graphic), periodic (Inline graphic), persistent (Inline graphic) asthma groups during 9 years of follow-up after randomization in the CAMP trial.